The research was led by Junwei Zheng, Taoyu Wu, and colleagues working with Jie Shi and Yan Sun at Peking University’s National Institute on Drug Dependence, together with Sizhi Ai at Guangzhou Medical University. Between June 2023 and October 2024, the team recruited right-handed men aged 18 to 45 who met the diagnostic criteria for etomidate use disorder under the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, alongside age-matched healthy male controls. All participants were assessed in Guangzhou, and the study received ethics approval from Peking University Health Science Center with written informed consent from every participant. By restricting the sample to men within a defined age band, the investigators controlled for the hormonal and anatomical variability that often complicates addiction neuroimaging studies.

The experiment centered on a cue-reactivity paradigm, a standard but powerful technique in addiction science. Participants viewed images associated with the drug alongside neutral pictures, while researchers measured how the brain responded to each category. Because craving unfolds on multiple timescales, from milliseconds to seconds, the team deliberately paired two complementary imaging technologies. Electroencephalography captures the brain’s electrical activity with millisecond precision through electrodes on the scalp, while functional magnetic resonance imaging tracks changes in blood oxygenation that mark where neural activity is concentrated over seconds. Independent cohorts completed each modality, allowing the researchers to test whether the electrical and hemodynamic signatures of craving converged on the same circuitry.

The EEG findings were striking. When people with etomidate use disorder viewed drug-related images, their brains produced markedly amplified late positive potentials, a slow electrical wave that emerges roughly 300 milliseconds after a stimulus and peaks over frontocentral electrode sites. The late positive potential has long been treated as an index of motivated attention: the brain flagging something as salient and worth allocating resources to. In this study, the size of the etomidate-related signal correlated directly with participants’ subjective ratings of craving, measured with a desire-for-drug questionnaire. In other words, the brains of dependent users were not passively registering the pictures; they were actively and involuntarily magnifying their importance, and the degree of that amplification tracked how strongly each individual wanted the drug at that moment.

The fMRI data told a spatially precise story that converged with the electrical one. Drug cues triggered hyperactivation in two regions: the temporoparietal junction, an area at the intersection of temporal and parietal cortex involved in attentional orienting and salience detection, and the ventrolateral prefrontal cortex, a region classically associated with cognitive control and the regulation of impulses. Hyperactivation of the ventrolateral prefrontal cortex might sound like a signature of stronger control, but the connectivity analysis revealed something more troubling about what that activation was actually doing.

To move beyond simple co-activation maps, the researchers applied dynamic causal modeling, a computational framework that estimates the direction and sign of influences between brain regions rather than merely noting which areas light up together. The signed connectivity parameters exposed a critical abnormality: in the etomidate group, the ventrolateral prefrontal cortex exerted abnormal inhibitory modulation over the temporoparietal junction, and crucially, the strength of that inhibition was linked to craving severity. Participants with weaker inhibitory modulation reported higher subjective craving. This finding reframes the role of the prefrontal cortex in the disorder. Rather than simply failing to engage, the control system appears to be miswired, its top-down signal to the attention-grabbing temporoparietal junction weakened precisely when it would be needed most to disengage from drug-related cues.

Structural MRI added a third and sobering layer of evidence. Using surface-based morphometry to measure cortical thickness across the entire brain, the team identified widespread thinning among individuals with etomidate use disorder, spanning prefrontal, parietal, occipitotemporal, and limbic regions. Cortical thinning in these territories has been reported in other substance use disorders and is generally interpreted as reflecting chronic neuroadaptation, whether through synaptic pruning, glial changes, or loss of dendritic complexity. That etomidate, a drug once considered relatively benign because of its rapid clearance and organ-sparing profile, is associated with structural changes across such a broad cortical expanse underscores that apparent pharmacological safety in the anesthetic context says little about safety under the repeated, escalating exposure patterns of misuse.

Etomidate’s pharmacology makes the findings biologically coherent. The drug is a GABA-A receptor positive allosteric modulator, and the GABAergic system is deeply intertwined with the reward and executive circuits implicated in every major addiction. Chronic exposure to substances that enhance inhibitory signaling forces the brain to recalibrate, and those recalibrations plausibly extend to the prefrontal networks that govern attention and impulse regulation. The study’s convergent design strengthens this interpretation: an electrical marker of exaggerated salience attribution, a hemodynamic marker of cue-driven hyperactivation, a connectivity marker of impaired top-down inhibition, and a structural marker of cortical compromise all point toward the same VLPFC-TPJ circuit as the neural seat of etomidate craving.

What elevates the study from descriptive to clinically consequential is the target it nominates. Non-invasive brain stimulation techniques, including transcranial magnetic stimulation and transcranial direct current stimulation, can modulate prefrontal activity with growing precision, and randomized trials in other addictions have already explored the ventrolateral prefrontal cortex as a stimulation site. If weakened VLPFC-to-TPJ inhibition is genuinely causal in maintaining craving, then restoring that inhibitory modulation becomes a testable therapeutic hypothesis, one that could be evaluated with stimulation protocols, neurofeedback, or even pharmacological agents that strengthen prefrontal function. The authors position the VLPFC-TPJ circuit explicitly as a promising neuromodulation target for treating etomidate use disorder, a framing that could accelerate translational work in a field that currently has no approved pharmacological treatment.

The study’s limitations invite caution and future work. The cohort was restricted to right-handed men, so the findings cannot yet be generalized to women or to patterns of use in other populations, and the case-control design cannot establish whether the cortical thinning preceded drug use or resulted from it. Longitudinal follow-up, ideally beginning before dependence develops, will be needed to disentangle cause from consequence. Still, as a first multimodal portrait of an emerging and poorly understood form of addiction, the work delivers something rare: a mechanistically specific, biologically grounded, and clinically actionable account of craving. At a moment when etomidate misuse is escalating globally, that combination may prove exactly what public health responses have been missing.

Subject of Research: Neural mechanisms of cue-induced craving and cortical structural changes in etomidate use disorder

Article Title: Multimodal neuroimaging of cue-induced craving and cortical alterations in etomidate use disorder

Article References: Multimodal neuroimaging of cue-induced craving and cortical alterations in etomidate use disorder. (n.d.). https://doi.org/10.1186/s12916-026-05253-5

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05253-5

Keywords: etomidate use disorder, drug craving, cue reactivity, EEG, fMRI, late positive potential, ventrolateral prefrontal cortex, temporoparietal junction, dynamic causal modeling, cortical thickness, GABA-A receptor, addiction neuroscience

The significance of self-administration models in addiction neuroscience is difficult to overstate. Unlike passive drug exposure experiments, in which the investigator simply injects an animal with a drug and observes the consequences, self-administration paradigms allow the animal itself to control when and how much drug it receives, typically by pressing a lever or poking its nose into a port. This voluntary element matters enormously. It allows investigators to dissociate the behavioral and neural mechanisms that motivate drug seeking and taking from the pharmacological effects of drug exposure itself, a distinction that lies at the heart of modern addiction research. Compulsive drug taking, relapse after abstinence, and the escalation of intake over time are all phenomena that only emerge when the animal has agency over its own drug consumption.

The intellectual lineage of this approach stretches back more than eight decades. As the authors note in their News and Views commentary accompanying the protocol, the earliest demonstrations that animals will work to obtain drugs appeared in the comparative psychology literature of 1940, when Spragg reported that chimpanzees would manipulate mechanisms to gain access to morphine. In the mid-1950s, Headlee, Coppock, and Hichols described intravenous morphine administration procedures in the Journal of Pharmaceutical Sciences, laying groundwork for controlled delivery of drugs into the bloodstream of laboratory animals. These early efforts culminated in a landmark 1962 study by James Weeks, published in Science, which established the operant intravenous drug self-administration procedure in rats—a technique that remains the workhorse of preclinical addiction research to this day.

The field built rapidly on that foundation. Thompson and Schuster demonstrated in 1964 that the principles of operant conditioning could be applied to morphine self-administration, and Risner and Jones extended the approach in 1975 to compare the reinforcing effects of different drugs. By 1991, Carney and colleagues were using self-administration procedures to study stimulant pharmacology, and the paradigm had become a standard screen for the abuse liability of novel compounds. A 2020 review by Venniro, Banks, Heilig, Epstein, and Shaham in Nature Reviews Neuroscience synthesized how decades of self-administration research had refined the field’s understanding of the neural circuits of drug reward, relapse, and the economic and social factors that influence drug taking. The historical arc is clear: each generation of methodological refinement has allowed sharper questions to be asked about why drugs are so compelling.

What the new protocol adds is the head-fixed dimension. In a conventional self-administration chamber, a mouse moves freely, presses levers, and receives intravenous infusions through a catheter implanted in its jugular vein. This arrangement is behaviorally rich but experimentally constrained. The animal’s head moves unpredictably, which degrades optical recordings, complicates the delivery of precisely timed sensory stimuli, and makes it nearly impossible to hold a microscope objective or a stimulus display in a fixed relationship to the animal’s eyes and whiskers. Head fixation solves these problems. With the skull rigidly stabilized, researchers can perform stable two-photon imaging of the same population of neurons across many sessions, deliver visual or auditory cues with millisecond precision, and apply optogenetic or pharmacological manipulations to genetically identified circuits while the animal is actively working for drug.

Combining head fixation with intravenous self-administration, however, is far from trivial, and this is precisely where the protocol makes its contribution. The authors provide step-by-step instructions for assembling the necessary hardware, integrating the head-fixation apparatus with the operant response devices and the infusion system that delivers drug through the implanted catheter. The technical challenges are considerable: the catheter must remain patent across repeated sessions while the animal is restrained; the operant manipulandum must be positioned so that a head-fixed mouse can respond comfortably; and the infusion line must be routed so that drug delivery is synchronized with the animal’s responses without introducing movement artifacts or leaks. By documenting these details, the protocol lowers the barrier for laboratories that want to adopt the technique without months of trial and error.

The timing of this methodological advance reflects a broader convergence in the field. A companion protocol by Doncheck and colleagues, also published in Nature Protocols in 2026 and cited in the commentary, indicates that head-fixed drug self-administration is emerging as a coherent methodological platform rather than the idiosyncratic setup of a single laboratory. Meanwhile, recent work published in Neuron in 2024 by Paniccia and colleagues demonstrated the scientific payoff of head-fixed approaches, and a 2021 study by Vollmer and colleagues in Frontiers in Behavioral Neuroscience explored related territory in freely moving animals. Together, these publications sketch a research landscape in which the voluntary taking of intravenous drugs can finally be observed with the full arsenal of modern circuit neuroscience.

For researchers weighing whether to adopt the technique, the trade-offs are worth understanding. Freely moving self-administration preserves the naturalistic ethology of drug seeking—the animal navigates its environment, approaches the drug source, and integrates spatial and contextual cues into its behavior. Head-fixed preparations sacrifice some of that naturalism in exchange for experimental control and optical stability. The authors’ framing suggests that the two approaches should be viewed as complementary rather than competing: freely moving studies establish the validity of a behavioral phenomenon, while head-fixed preparations dissect its circuit-level mechanisms with cellular precision. A protocol that makes the head-fixed variant accessible and reproducible therefore expands the toolkit available to the field rather than replacing the established one.

The potential applications span the major questions of addiction neuroscience. With a head-fixed mouse pressing a port for intravenous cocaine, opioid, or other drug infusions, investigators could track how neurons in the prefrontal cortex, nucleus accumbens, dorsal striatum, or amygdala change their activity as drug seeking becomes habitual, as intake escalates, or as cues that predict drug availability come to drive behavior. They could test whether manipulating specific projections alters the propensity to seek drug, and they could do so across many consecutive sessions with imaging planes held perfectly stable. Because the animals are mice rather than rats, the full power of mouse genetics—cell-type-specific reporters, conditional knockouts, and activity-dependent labeling—becomes available to self-administration research in ways that were previously cumbersome.

As with any methodological innovation, the ultimate test will be how widely the technique is adopted and what it reveals. The authors declare no competing interests, and the protocol, published as a U.S. Government work, is accompanied by supplementary information including an additional figure and references to support implementation. For a field that has spent more than sixty years refining the operant self-administration paradigm since Weeks first described it in Science, the arrival of a validated head-fixed variant marks a genuine expansion of the frontier. If it delivers on its promise, the coming years should see drug self-administration experiments in which every lever press is paired with a window into the living brain—bringing addiction neuroscience closer to the mechanistic depth that the problem of addiction demands.

Subject of Research: A protocol for performing intravenous drug self-administration in head-fixed mice to study the neural mechanisms of addiction.

Article Title: Head-fixed intravenous drug self-administration: a new frontier in addiction neuroscience

Article References: Negishi, K., D’Ottavio, G., & Shaham, Y. (2026). Head-fixed intravenous drug self-administration: a new frontier in addiction neuroscience. Nature Protocols. https://doi.org/10.1038/s41596-026-01438-7

Image Credits: AI Generated

DOI: 10.1038/s41596-026-01438-7

Keywords: addiction neuroscience, drug self-administration, head-fixed mice, intravenous drug delivery, Nature Protocols, behavioral neuroscience, two-photon imaging, operant conditioning, drug reward, relapse, NIDA, mouse models

Metacognition is often described as “thinking about thinking.” It is the mental faculty that allows a person to sense when they are unsure of an answer, to judge the accuracy of a memory before acting on it, and to adjust behavior accordingly. In laboratory settings, metacognition is typically measured by asking participants to perform a perceptual or cognitive task and then to rate their confidence in each decision. Researchers then compute a metric known as metacognitive sensitivity — essentially, how well a person’s confidence ratings track their actual accuracy. A person with strong metacognitive sensitivity is confident when correct and doubtful when wrong; a person with impaired metacognition loses this correspondence, becoming unable to distinguish reliable internal signals from unreliable ones.

This capacity matters enormously in everyday life and, according to a growing body of addiction research, it may matter especially in the cycle of substance dependence. The predominant neurocognitive models of addiction hold that chronic drug use degrades the neural systems responsible for self-regulation, tipping the balance toward habitual, compulsive drug-seeking at the expense of deliberate, goal-directed behavior. If metacognitive monitoring is part of that self-regulatory architecture, then deficits in it could help explain one of the most perplexing features of addiction: the persistence of drug use despite obvious and repeated negative consequences. A person who cannot accurately appraise their own cognitive state may also be less equipped to appraise the mounting costs of their behavior, or to trust their own resolve when attempting abstinence.

Earlier studies in the field had reported reduced metacognitive accuracy in individuals with cocaine use disorder, but the reliability of those findings remained an open question. Small sample sizes, heterogeneous participant groups, and inconsistent methods for quantifying metacognition all left room for doubt about whether the observed deficits were genuine features of the disorder or artifacts of particular experiments. The new study was designed specifically to address this uncertainty through a confirmatory approach, meaning that it set out to test the previously reported association under carefully controlled and preregistered analytical conditions, using refined behavioral metrics that separate metacognitive sensitivity from the underlying task performance itself.

The research team assessed participants with cocaine use disorder alongside well-matched comparison participants, evaluating metacognition across cognitive tasks while also gathering detailed information about recent patterns of cocaine consumption. This dual focus proved crucial. The results indicated that metacognitive impairment was not simply a fixed trait of the disorder but was dynamically linked to the recency and intensity of drug use. Participants whose recent cocaine consumption was higher showed more pronounced deficits in their ability to monitor the accuracy of their own decisions, while those with longer periods of reduced use displayed comparatively better metacognitive performance. In other words, the internal compass that tells us how much to trust our own minds appears to be dulled by recent exposure to the drug and may partially recover as use declines.

Technically, the study relied on signal-detection-theoretic frameworks to disentangle the components of metacognitive performance. Simple accuracy on a task and confidence in one’s answers can be confounded — a participant who performs poorly on everything might also report uniformly low confidence, without any true metacognitive deficit. Modern metrics such as meta-d, which estimates metacognitive sensitivity relative to task performance, allow researchers to ask whether an individual’s confidence judgments are informative above and beyond their raw accuracy. By applying such analyses in a confirmatory framework, the researchers could demonstrate that the impairment in cocaine use disorder specifically involves the monitoring layer of cognition rather than a generalized cognitive slowdown or lack of engagement with the tasks. This distinction carries theoretical weight, because it points to disruption in neural circuits — often implicating the prefrontal cortex and its connections to parietal and limbic regions — that are thought to support self-directed evaluation.

The prefrontal cortex has long been identified as a region vulnerable to the effects of chronic cocaine exposure. Neuroimaging and neuropsychological studies have repeatedly documented alterations in prefrontal gray matter volume, white matter integrity, and metabolic activity in people with cocaine use disorder. Because these same frontal networks are central to metacognitive processing in healthy individuals, the convergence of evidence is striking: the brain systems that generate our sense of confidence and uncertainty are precisely those most affected by prolonged stimulant use. Recent drug use, by modulating dopaminergic signaling and prefrontal function acutely as well as chronically, may therefore exert a double burden — degrading the machinery of self-monitoring at the moment when recovering individuals most need it.

The clinical implications of this work are potentially far-reaching. Addiction treatment typically depends on the patient’s ability to recognize lapses in control, anticipate high-risk situations, and honestly evaluate progress. Metacognitive impairment could undermine each of these processes, explaining why some individuals struggle with self-reported insight into their condition — a phenomenon sometimes described clinically as impaired awareness of illness in addiction. If recent drug use exacerbates these monitoring deficits, then treatment programs might benefit from incorporating strategies that scaffold self-assessment: structured feedback, external monitoring tools, and therapeutic techniques such as metacognitive training or mindfulness-based relapse prevention, which explicitly aim to strengthen awareness of one’s own cognitive and emotional states. Conversely, the observed link between reduced recent use and better metacognition offers a hopeful message: the capacity for accurate self-reflection may be at least partially restorable during abstinence or sustained reduction in use.

At the same time, the researchers are careful to frame the findings within their limits. Confirmatory evidence strengthens confidence in the association between recent cocaine use and metacognitive impairment, but longitudinal studies remain essential to determine the direction of causality. It is plausible that impaired metacognition predisposes individuals to heavier use — poor self-monitoring could erode the brakes on consumption — while acute and chronic drug effects, in turn, deepen the impairment, creating a self-reinforcing loop. Disentangling these pathways will require repeated-measures designs that track metacognitive performance and drug use over time within the same individuals. Future research may also extend the paradigm to other substance use disorders to determine whether metacognitive dysfunction is a shared mechanism of addiction or a distinctive signature of stimulant dependence.

What the study already establishes, however, is a meaningful step forward for the cognitive neuroscience of addiction. By confirming, with methodological rigor, that cocaine use disorder involves a genuine and use-dependent impairment of metacognition, the work reframes the disorder not merely as a failure of willpower or reward processing, but as a disruption of the mind’s ability to audit itself. This perspective resonates with the lived experience of many people with addiction, who often describe acting on autopilot, surprised by their own behavior after the fact. Understanding that surprise itself — the failure to foresee and monitor one’s own lapses — has a measurable cognitive basis could reduce stigma and inform more compassionate, biologically grounded approaches to treatment. As research continues, the internal gauge of confidence and doubt may prove to be a promising therapeutic target, one whose recovery could mark a turning point in the journey out of dependence.

Subject of Research: Metacognitive impairment in cocaine use disorder and its relationship to recent drug use

Article Title: Metacognitive impairment in cocaine use disorder: confirmatory evidence for the effects of recent drug use

Article References: Moeller, S. J., McClain, N., Abeykoon, S., Alia-Klein, N., & Goldstein, R. Z. (2026). Metacognitive impairment in cocaine use disorder: confirmatory evidence for the effects of recent drug use. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04406-7

Image Credits: AI Generated

DOI: 10.1038/s41398-026-04406-7

Keywords: cocaine use disorder, metacognition, substance abuse, prefrontal cortex, self-monitoring, Translational Psychiatry, addiction neuroscience, relapse prevention, cognitive impairment, dopamine, confidence judgments, abstinence